DEXWireNews

Chembio Diagnostics 20% upside

Pembelian
NASDAQ:CEMI   None
Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The firm expanding its product portfolio based upon the proprietary Dual Path Platform, which uses a small drop of blood from the fingertip to provide cost-effective diagnostic results in approximately 15 minutes. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Hauppauge, NY.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.